Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Shionogi Earmarks 20 Billion Yen in Strategic R&D Investment
May 10, 2018
- Shionogi’s Net Profit Crosses 100 Billion Yen Mark in FY2017
May 10, 2018
- Takeda’s Shire Deal Inspiring for Japan Industry Peers: Mitsubishi Tanabe Chief
May 10, 2018
- Mitsubishi Tanabe Logs Record Sales, but Profits Sag on Higher R&D/SGA Costs
May 10, 2018
- AbbVie’s JAK1 Inhibitor Upadacitinib Hits Primary Endpoints in PIIb/III Study in Japanese RA Patients
May 10, 2018
- Taiho’s Lonsurf Extends OS in PIII in Patients with Metastatic Gastric Cancer
May 10, 2018
- Pfizer Japan Cedes Crown as Top Rep Holder as Global Players Continue to Seek Leaner Sales Force: Survey
May 9, 2018
- Takeda Attracted to Shire’s High Profitability, Rare Disease Pipeline: CEO
May 9, 2018
- Quizartinib Prolongs OS in 2nd-Line AML: Daiichi Sankyo
May 9, 2018
- Daiichi Sankyo, Kaketsuken Terminate Vaccine Sales Partnership
May 9, 2018
- US FDA Approves Myrbetriq/Vesicare Combination Therapy for OAB: Astellas
May 9, 2018
- Kissei Mulls Over Urief AG Launch
May 9, 2018
- MHLW Official Hails Takeda’s Shire Takeover
May 9, 2018
- Takeda Cuts Deal to Acquire Shire in Japan’s Biggest Buyout
May 8, 2018
- Spiolto Improves Lung Function in Japanese COPD Patients against Spiriva in Trial: BI
May 8, 2018
- XLH Drug Crysvita Now Available in US: Kyowa Kirin/Ultragenyx
May 8, 2018
- FDA OKs Label Update for Takeda/Lundbeck’s Trintellix
May 8, 2018
- Over 60% of Drug Makers Cut New Grad Hires in FY2018, Otsuka Tops List Again: Tally
May 8, 2018
- Kyowa Kirin to Focus on New Drugs in Europe, US to Achieve Midterm Targets: New President
May 7, 2018
- Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018
May 7, 2018
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…